CAMBRIDGE, England, June 25, 2015 /PRNewswire/ --
Aegate, the leading experts in medicines verification, held its second Partner Symposium today in Frankfurt, Germany.
(Logo: http://photos.prnewswire.com/prnh/20150610/748687 )
The first day of the Symposium heard from representatives from various national stakeholders, including a case study from the Belgian APB, local industry experts including a German parallel trade and a presentation by Domino. The focus of the day was the Falsified Medicines Directive (FMD).
The day's keynote speech was made by Dr Martin Hug, from the Apotheke des Universitätsklinikums, who spoke about 'Medication Supply from Prescription to Safety - a Pharmacist's View'.
There followed a lively panel debate on how best to move forward with preparation for the Falsified Medicines Directive and the unique challenges facing hospital pharmacy in the implementation of an authentication service. Aegate offered its experience and expertise to the German stakeholders gained in both retail and hospital environments.
All parties present agreed on the need to take a more active role to progress the issues raised by the FMD, the panel saw the benefits of building on Aegate's practical experience.
The Symposium will continue tomorrow where participants will hear more about the UK hospital pilot.
About Aegate
With a documented history of some 3.3 billion medicines scanned to date with an average rate of 200,000 transactions per hour across 20,000 dispensing points, Aegate is the principal active market leader in medicines verification. Aegate's Reach, Assure and Protect services meets the needs of all stakeholders. Supported internationally by manufacturers and pharmacists alike, Aegate is a European company with offices throughout Europe. Our mission is to protect patients from falsified, recalled or expired medicines.
We operate a highly secure real‐time system to verify the authenticity of medicines. This operates seamlessly from manufacturer to pharmacy, and fully meets the requirements of European legislation for falsified medicines. The Aegate network also supports messaging services that provide additional information for the pharmacist at the point of dispense, such as regulatory or drug safety advice and patient education or adherence information.
For more information on Aegate, please visit http://www.aegate.com
Media contact information:
Miriam Foster
Head of Marketing & Communications
marketing@aegate.com
T: +44-1763-268160
Share this article